Company intelligence
Basking Biosciences, Inc.
Redefining the future of thrombosis treatment
About Basking Biosciences, Inc.
Basking Biosciences is a clinical-stage biopharmaceutical company redefining how potentially life-threatening blood clots are treated. Its novel, investigational therapies are designed to significantly improve safety and efficacy, broadening access to many more patients. Its lead program, BB-031, is the first rapid-onset, short-acting thrombolytic therapy with a reversal agent, currently in development for the treatment of acute ischemic stroke (AIS). By inhibiting von Willebrand Factor (vWF), a key driver in clot formation, BB-031 aims to deliver targeted, potent thrombolytic activity that could enable more patients to receive timely, life-saving treatment after stroke.
Verified activity
Signals from Basking Biosciences, Inc.
3 published signals
Research & Knowledge
Basking Biosciences, Inc. CEO Julia Owens will share updates on Basking’s clinical development progress in acute ischemic stroke, including the Phase 2 RAISE trial of BB-031 and recent Phase 1 results for BB-025.
Reported by Basking Biosciences, Inc.
Presence & Recognition
Basking Biosciences, Inc. CEO Julia Owens will give a corporate presentation at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 10.
Reported by Basking Biosciences, Inc.
Presence & Recognition
Basking Biosciences, Inc. is attending the Wells Fargo Healthcare Conference in Boston next week.
Reported by Julia Owens